摘要
目的检测从临床标本中分离出的78株变形杆菌对15种常用抗菌药物的体外活性,以及这些杆菌的产超广谱β-内酰胺酶(ESBLs),正确指导临床合理使用抗生素。方法用Viter-32全自动微生物分析仪对菌株进行鉴定、药敏分析及产ESBLs筛选。结果奇异变形杆菌的产ESBLs率为18.9%(10/53),普通变形杆菌的产酶率为9.5%(2/21)。第3代头孢菌素、亚胺培南、丁胺卡那霉素、替卡西林+棒酸等青霉素类/β-内酰胺酶抑制剂复合剂的耐药率均低于10%。结论实验室有必要加强对产ESBLs变形杆菌的检测,第3代头孢菌素、亚胺培南、丁胺卡那霉素、替卡西林加棒酸等青霉素类/β-内酰胺酶抑制剂复合剂是治疗变形杆菌感染的首选药物。
Objective To determine the activily of the 15 commonly used antibiotics against 78 strains of proteus isolated from clinical departments to guide the rational application of antibiotics.Methods The strains identification was performed by the VITEK-32,antibiotic susceptibilities of proteus isolates and screening ESBL-producing isolates were performed by the VITEK-32 too.Results The ESBL-producing rate of p.mirabilis was 18.9% and that of p.vulgaris was 9.5%.The resistant rate of proteus clinical isolates to third-generation cephalosporins,imipenem（IMP）,amikacin（AN） and ticarcillin/CA（TCC） was below 10%.Conclusion Clinical laboratories must strengthen determination of proteus of lactamase-producing isolates.Third-generation cephalosporins,imipenem（IMP）,amikacin（AN）and ticarcillin/CA（TCC）were of the first choice for the infections caused by proteus.
出处
《检验医学与临床》
CAS
2010年第12期1161-1162,共2页
Laboratory Medicine and Clinic
